Teva Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS INC
TEVA PHARMS INC has fifteen approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are three tentative approvals on TEVA PHARMS INC drugs.
There are two patent family members on TEVA PHARMS INC drugs in two countries and one hundred and twenty supplementary protection certificates in nineteen countries.
Summary for Teva Pharms Inc
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 15 |
| Ingredients: | 15 |
| NDAs: | 15 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 220276-003 | Nov 13, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 219134-002 | Jun 26, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | GLYCEROL PHENYLBUTYRATE | glycerol phenylbutyrate | LIQUID;ORAL | 218738-001 | Apr 15, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-002 | Jan 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-003 | Jan 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| European Patent Office | 3692021 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1915993 | 92315 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE |
| 1343782 | C300456 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
| 1343782 | 10C0037 | France | ⤷ Start Trial | PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614 |
| 1294378 | 2010C/018 | Belgium | ⤷ Start Trial | PRODUCT NAME: ELTROMBOPAG, OPTIONNELLEMENT SOUS FORME DE SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS UN HYDRATE); AUTHORISATION NUMBER AND DATE: EU/1/10/612/001 20100315 |
| 0443983 | C300445 | Netherlands | ⤷ Start Trial | PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
